-
公开(公告)号:US20210079023A1
公开(公告)日:2021-03-18
申请号:US17046498
申请日:2019-04-12
申请人: MEDIMMUNE LIMITED
IPC分类号: C07D519/00 , A61P35/00 , A61K47/68
摘要: A compound with the formula I: (I) and salts and solvates thereof, wherein: R″ is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.
-
公开(公告)号:US10695439B2
公开(公告)日:2020-06-30
申请号:US16076588
申请日:2017-02-10
申请人: Medimmune Limited
IPC分类号: A61K47/68 , A61P35/00 , A61K45/06 , C07D519/00
摘要: A conjugate of formula (I): L-(DL)p (I) wherein L is a Ligand unit, D is a Drug Linker unit of formula (II) wherein p is an integer of from 1 to 20.
-
公开(公告)号:US10646584B2
公开(公告)日:2020-05-12
申请号:US16412138
申请日:2019-05-14
申请人: MEDIMMUNE LIMITED
发明人: Philip Wilson Howard
IPC分类号: C07D487/04 , A61K47/68 , C07D519/00 , A61K45/06 , A61K47/65
摘要: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.
-
公开(公告)号:US10576164B2
公开(公告)日:2020-03-03
申请号:US15786055
申请日:2017-10-17
申请人: MedImmune Limited , Genentech, Inc.
IPC分类号: A61K47/68 , A61P35/00 , C07D498/14 , C07D519/00 , A61K31/5517 , C07D487/04 , C07D487/16
摘要: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T′ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X′ is 3 to 12 atoms; and X and X′ are independently selected from O, S and N(H).
-
公开(公告)号:US10543279B2
公开(公告)日:2020-01-28
申请号:US16096631
申请日:2017-04-28
申请人: MEDIMMUNE LIMITED
IPC分类号: A61K47/54 , A61P35/00 , C07D519/00 , A61K45/06
摘要: A conjugate of formula (I): L-(DL)p, wherein L is a Ligand unit, D is a Drug Linker unit of formula (II), wherein p is an integer of from 1 to 20.
-
公开(公告)号:US10392393B2
公开(公告)日:2019-08-27
申请号:US16072116
申请日:2017-01-26
申请人: Medimmune Limited
IPC分类号: C07D487/04 , C07D403/12 , A61P35/00 , A61K47/60 , A61K47/65
摘要: A compound with the formula I, wherein R2 is of formula II, where A is a C5-7 aryl group, X is selected from the group consisting of: OH, SH, CO2H, COH, N═C═O, NHNH2, CONHNH2, (III), (IV), and NHRN, wherein RN is selected from H and C1-4 alkyl, and either: (i) Q1 is a single bond, and Q2 is selected from a single bond and —Z—(CH2)n—, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q1 is —CH═CH—, and Q2 is a single bond; and its conjugates.
-
公开(公告)号:US09919056B2
公开(公告)日:2018-03-20
申请号:US14434826
申请日:2013-10-11
IPC分类号: A61K39/395 , A61K47/48 , A61K31/551 , C07K16/10 , C07K16/28 , A61K31/5517 , A61K45/06 , A61K39/00
CPC分类号: A61K47/6803 , A61K31/551 , A61K31/5517 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6867 , A61K2039/505 , C07K16/1063 , C07K16/2803 , C07K16/2851 , C07K2317/24 , C07K2317/40 , C07K2317/56 , C07K2317/73
摘要: Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers.
-
公开(公告)号:US09649390B2
公开(公告)日:2017-05-16
申请号:US14774535
申请日:2014-03-13
申请人: MEDIMMUNE LIMITED
IPC分类号: C07D487/04 , A61K47/48 , C07D519/00 , A61K31/5517 , C07K16/28 , C07K16/40
CPC分类号: A61K47/48646 , A61K31/5517 , A61K47/6803 , A61K47/6855 , A61K47/6871 , C07D519/00 , C07K16/2863 , C07K16/40 , C07K2317/92
摘要: A conjugate of formula (A):
-
公开(公告)号:US20160256561A1
公开(公告)日:2016-09-08
申请号:US15028585
申请日:2014-10-10
CPC分类号: A61K47/48569 , A61K45/06 , A61K47/6803 , A61K47/6855 , C07K16/32
摘要: Conjugates of specific PBD dimers with an antibody that that binds to HER2, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.
摘要翻译: 具有与HER2结合的抗体的特异性PBD二聚体的结合物,所述抗体包含具有根据SEQ ID NO.1的序列的VH结构域。 1。
-
公开(公告)号:US20150283258A1
公开(公告)日:2015-10-08
申请号:US14434812
申请日:2013-10-11
IPC分类号: A61K47/48 , A61K31/5517 , A61K45/06 , C07K16/18
摘要: Conjugates of an antibody that binds to PSMA with PBD dimers.
摘要翻译: 使用PBD二聚体结合PSMA的抗体的缀合物。
-
-
-
-
-
-
-
-
-